Interestingly, administering 1-MT with anti-CTLA-4 and anti-PD-L1 monoclonal antibodies produced a 100% long-term survival rate in glioma-bearing mice (249), an improvement over the 90% long-term survival rate in anti-CTLA-4 and anti-PD-L1 therapies alone. Here, CTLA4 is linked to glioma.